In the context of psychotherapy, MDMA is a psychedelic that has a considerable quantity of data supporting its efficacy in its role as an adjunct to therapy. With the completion of the second and final phase three clinical trial of MDMA-assisted psychotherapy for treatment of PTSD in 2022, and the data available from those trials–MAPP1 demonstrated that 88% of participants displayed significant improvements, 67% no longer met criteria for diagnosis, MAPP2 showed results from participants having moderate PTSD, not exclusively severe, and lastly, MAPP2 enrolled nearly twice as many participants of color–it is evident that there will be a New Drug Application in the near future (Kuntz, 2022). This presents a potentially very promising future for PTSD patients who have yet to find relief from their symptoms in psychotherapy or psychopharmacology.